Gain Therapeutics Inc. (GANX) is a clinical-stage biotechnology company advancing next-generation allosteric therapies for neurodegenerative and rare diseases. Its lead candidate, GT-02287, is in clinical development for Parkinson's disease with or without a GBA1 mutation, supported by promising preclinical and early clinical data. With enrollment completed in its Phase 1b study and multiple upcoming milestones, Gain is positioned for important readouts that could shape its trajectory in 2026.
Stock Performance
For comments and feedback contact: editorial@rttnews.com
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.